SCHEMBL16184716

SCHEMBL16184716

COc1cc(-c2cccc(F)c2)cc2c(N3CCCC3=O)nc(-c3cccnc3)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ GAA P10253 2/20 0.45
▸ PIM1 P11309 2/20 0.42
▸ CYP11B1 P15538 5/20 0.41
▸ CYP11B2 P19099 5/20 0.41
▸ HCRTR1 O43613 3/20 0.39
▸ HCRTR2 O43614 3/20 0.39
▸ NPC1 O15118 1/20 0.37
▸ PDE2A O00408 3/20 0.37
▸ PDE5A O76074 3/20 0.37
▸ PDE11A Q9HCR9 3/20 0.37
▸ PDE10A Q9Y233 3/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184799 0.95 MAPT (0.46) MAPTALDH1A1GAAPIM1CYP11B1
SCHEMBL16184734 0.92 MAPT (0.45) MAPTALDH1A1GAAPIM1CYP11B1
SCHEMBL16184815 0.91 MAPT (0.44) MAPTALDH1A1GAAPIM1CYP11B1
SCHEMBL16184783 0.89 MAPT (0.43) MAPTALDH1A1GAAPIM1CYP11B1
SCHEMBL16184766 0.89 MAPT (0.43) MAPTALDH1A1GAAPIM1CYP11B1
SCHEMBL16184749 0.88 MAPT (0.43) MAPTALDH1A1GAAPIM1CYP11B1
SCHEMBL16184706 0.88 ALDH1A1 (0.49) MAPTALDH1A1GAANPC1PDE2A
SCHEMBL16184054 0.88 ALDH1A1 (0.47) MAPTALDH1A1GAANPC1PDE2A
SCHEMBL16184701 0.87 MAPT (0.46) MAPTALDH1A1GAAPIM1CYP11B1
SCHEMBL16184712 0.87 ALDH1A1 (0.51) MAPTALDH1A1GAANPC1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAPT 509/4885ALDH1A1 1687/4885GAA 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback